Evaluation of ethical analyses in seven reports from the European Network for Health Technology Assessment

16 July 2019 - Ethics has been considered among the core domains of health technology assessment, but there are still ...

Read more →

Early benefit assessment reveals weaknesses in the development of new drugs

11 July 2019 - Analysis of 216 AMNOG assessments in the BMJ / Proposals for more targeted drug development ...

Read more →

New drugs: where did we go wrong and what can we do better?

10 July 2019 - More than half of new drugs entering the German health care system have not been shown to ...

Read more →

Biomarker-based cancer diagnostics: German pricing regulator sets high validation and reimbursement standards for novel diagnostic methods

10 July 2019 - On 20 June 2019, for the first time, the German Federal Joint Committee (G-BA), made the resolution ...

Read more →

Report calls for European funding reform for gene therapies

8 July 2019 - New payment models, dedicated investment, and better health technology assessment are among a raft of changes ...

Read more →

UK, Germany, dissociate from WHO drug pricing resolution

8 June 2019 - The passage of a landmark resolution on improving the transparency of markets for medicines at the latest ...

Read more →

Europe responding to gene therapy challenge, but picture remains fragmented

20 May 2019 - Germany, Italy and England using outcomes-based deals. ...

Read more →

Nivolumab and ipilimumab: drug combination has added benefit in advanced renal cell carcinoma

15 May 2019 - There are no serious disadvantages in terms of overall survival. ...

Read more →

Apalutamide in prostate cancer: indication of significant added benefit

2 May 2019 - Study shows significant slowing of symptomatic progression. ...

Read more →

Ribociclib in advanced breast cancer: survival benefits, but also severe side effects

15 April 2019 - In the overall view, an added benefit is not proven. ...

Read more →

Single-payer drug pricing in a multi-payer health system: does Germany offer a model for the US?

22 March 2019 - An increasing number of presidential hopefuls, most recently Senator Kamala Harris, are proposing “single payer” or “Medicare ...

Read more →

Numerous G-BA decisions on new medicines - five active substances with considerable added value

22 March 2019 - On Friday in Berlin, the Federal Joint Committee (G-BA) made numerous decisions on the extent of the ...

Read more →

Methodological problems in the method used by IQWiG within early benefit assessment of new pharmaceuticals in Germany

5 March 2019 - The decision matrix applied by the IQWiG for the quantification of added benefit within the early benefit ...

Read more →

Germany agrees on new pharmaceutical bill

13 February 2019 - On 30 January, the German government has agreed on a draft Act for more safety in ...

Read more →

Erenumab in migraine: indication of a significant added benefit for certain patients

2 February 2019 - As a prophylaxis successful when other drug therapies are exhausted. ...

Read more →